Why the study?
Are direct oral anticoagulants reasonable alternatives to vitamin K antagonists for preventing and treating thromboembolic disease?
Are direct oral anticoagulants reasonable alternatives to vitamin K antagonists for preventing and treating thromboembolic disease?
Direct oral anticoagulants are reasonable, convenient alternatives to vitamin K antagonists for thromboembolic disease management, though bleeding risks remain a consideration.
Answers are grounded in this paper and cite their sources.
Supports new oral anticoagulant convenience over vitamin K antagonists; leaves open bleeding risk optimization in routine practice.
Dabigatran (a direct thrombin inhibitor) and rivaroxaban, apixaban, and edoxaban (direct activated factor X inhibitors) are increasingly being used in clinical practice. Compared with vitamin K antagonists, they are more convenient, do not require laboratory monitoring, have limited drug and food interactions, and have fixed dosages suitable for most patients. But the shortcomings of these agents can jeopardize their efficacy and increase the risk of bleeding. Their future role in preventing and treating thromboembolic disease will depend on building clinical experience, but current evidence indicates that they are reasonable alternatives to vitamin K antagonists.
No takes yet. Share an insight, caveat, or question.
Roca et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: